Abstract:International Journal of Laboratory HematologyVolume 43, Issue 3 p. e145-e147 LETTER TO THE EDITOR Identification and lineage restriction analyses of preleukemia cells in a sporadic biallelic CEBPA mutated acute myeloid leukemia patient Yuan Chen, Yuan Chen orcid.org/0000-0002-2923-6880 State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorQian Liu, Qian Liu State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorZhongxun Shi, Zhongxun Shi State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorGuangji Zhang, Guangji Zhang Leukaemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorMin Wang, Min Wang State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorYingchang Mi, Yingchang Mi State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Disease, Leukaemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorHui Wei, Corresponding Author Hui Wei weihui@ihcams.ac.cn State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Disease, Leukaemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China Correspondence Jianxiang Wang and Hui Wei, State Key laboratory of Experimental Hematology, Leukaemia center, National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Nanjing Rd 288, Tianjin, 300020, China. Emails: wangjx@ihcams.ac.cn (JW); weihui@ihcams.ac.cn (HW)Search for more papers by this authorJianxiang Wang, Corresponding Author Jianxiang Wang wangjx@ihcams.ac.cn State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Disease, Leukaemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China Correspondence Jianxiang Wang and Hui Wei, State Key laboratory of Experimental Hematology, Leukaemia center, National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Nanjing Rd 288, Tianjin, 300020, China. Emails: wangjx@ihcams.ac.cn (JW); weihui@ihcams.ac.cn (HW)Search for more papers by this author Yuan Chen, Yuan Chen orcid.org/0000-0002-2923-6880 State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorQian Liu, Qian Liu State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorZhongxun Shi, Zhongxun Shi State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorGuangji Zhang, Guangji Zhang Leukaemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorMin Wang, Min Wang State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorYingchang Mi, Yingchang Mi State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Disease, Leukaemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, ChinaSearch for more papers by this authorHui Wei, Corresponding Author Hui Wei weihui@ihcams.ac.cn State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Disease, Leukaemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China Correspondence Jianxiang Wang and Hui Wei, State Key laboratory of Experimental Hematology, Leukaemia center, National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Nanjing Rd 288, Tianjin, 300020, China. Emails: wangjx@ihcams.ac.cn (JW); weihui@ihcams.ac.cn (HW)Search for more papers by this authorJianxiang Wang, Corresponding Author Jianxiang Wang wangjx@ihcams.ac.cn State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Disease, Leukaemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China Correspondence Jianxiang Wang and Hui Wei, State Key laboratory of Experimental Hematology, Leukaemia center, National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Nanjing Rd 288, Tianjin, 300020, China. Emails: wangjx@ihcams.ac.cn (JW); weihui@ihcams.ac.cn (HW)Search for more papers by this author First published: 23 December 2020 https://doi.org/10.1111/ijlh.13449 Chen and Liu contributed equally to this work. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume43, Issue3June 2021Pages e145-e147 RelatedInformation

Correction to "Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia".

Targeted Inhibition Of Stat/Tet1 Axis As A Therapeutic Strategy For Acute Myeloid Leukemia (Vol 8, 2017)

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Correction to “design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure”

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia

Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

Correction to Acenaphtho[1,2-b]pyrrole-Based Selective Fibroblast Growth Factor Receptors 1 (FGFR1) Inhibitors: Design, Synthesis, and Biological Activity

Correction to Intracellular Fate of Nanoparticles with Polydopamine Surface Engineering and a Novel Strategy for Anti-Exocytosis Enhanced, Lysosome Impairment-Based Cancer Therapy

Correction to Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor.

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Correction to “Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies”

Correction to Receptor and Microenvironment Dual-Recognizable Nanogel for Targeted Chemotherapy of Highly Metastatic Malignancy

Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia

Identification and Lineage Restriction Analyses of Preleukemia Cells in a Sporadic Biallelic CEBPA Mutated Acute Myeloid Leukemia Patient

An Adamantyl-Substituted Retinoid-Derived Molecule That Inhibits Cancer Cell Growth and Angiogenesis by Inducing Apoptosis and Binds to Small Heterodimer Partner Nuclear Receptor: Effects of Modifying Its Carboxylate Group on Apoptosis, Proliferation, and Protein-Tyrosine Phosphatase Activity

Correction to “identification of Tumor Specific Peptide As EpCAM Ligand and Its Potential Diagnostic and Therapeutic Clinical Application”

Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Correction to "Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors"

Discovery and Characterization of a Novel Highly Potent and Selective Type II Native and Drug-Resistant V299L Mutant BCR-ABL Inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)